Navigation Links
Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
Date:4/24/2009

eVoucherRx lowers patients' financial responsibility for their diabetes therapy, positively influencing compliance and persistency; electronic coupon program works in real time at point of dispensing ACCU-CHEK(R) test strips.

INDIANAPOLIS, April 24 /PRNewswire/ -- Roche announced today the launch of its new eVoucherRx(TM) pilot program in California, designed to make it easier for patients with diabetes to receive their co-pay savings on ACCU-CHEK test strips. The program, active now at participating pharmacies, ensures patients with diabetes that their co-pay for ACCU-CHEK(R) test strips will not exceed $25. The program provides a discount of up to $40 per month, potentially lowering a patient's cost of blood glucose monitoring supplies by up to $480 per year.

eVoucherRx is a program that works in real time at the point of dispensing, which means patients do not need to do anything other than go to a participating pharmacy. To find a list of participating pharmacies, patients are encouraged to go online and visit www.accu-chek.com/evoucher.

"Lowering the patient's financial responsibility for diabetes therapy positively influences adherence and persistency in the self-management of their disease, especially during these challenging economic times," said Roche Vice President of Marketing Dan Kane. "eVoucherRx also helps prescribing physicians know that more of their patients will be able to afford their diabetes supplies. Our program that means less cost to our patients, it's seamless and hassle-free and it should lead to better health outcomes."

The eVoucherRx program is administered by RelayHealth for patients with commercial third-party health insurance. The program is not open to patients age 65 or older, cash-paying customers, patients on Medicare, Medicaid or those subsidized by other government-funded plans.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management--from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

    For further information, please contact:
    Julie Vincent
    Public Relations Manager
    ACCU-CHEK(R) Brand
    julie.vincent@roche.com
    317-521-1910


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves New Roche West Nile Virus Blood Screening Test
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
6. MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement
7. Nations Largest Healthcare Alliance Adds Roche HIV-1 Test to Existing Contract
8. Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX Systems to 10 instruments
9. Roche Extends Tender Offer for Ventana
10. Roche Offers Innovative Website Designed to Empower Cancer Patients
11. Neurochem reports results for third quarter of fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood ... his medical and surgical expertise. Technically known as deoxycholic acid or previously as ... a non-surgical alternative for reduction of fat below the chin (aka the “double ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... disorder treatment helps to reduce the frequency and level of relapse. ... Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the recovery ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> http://www.researchandmarkets.com/research/jsc97m/global ) ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, players ... offering. --> Research and ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest ... is the first of its kind in the ... tattoos through advanced laser treatment. The physician-owned and ... Suncoast by storm with its revitalizing ... and advanced multi-wavelength Astanza Trinity technology. ...
(Date:2/5/2016)... Feb. 5, 2016 Dehaier Medical Systems ... the "Company"), which develops, markets and sells medical ... China and international markets, today ... aims to concentrate the Company,s resources to develop ... business and to focus more on its major ...
Breaking Medicine Technology: